Stem Cells

Stem cells have the ability to self-renew and multiply resulting in new generations. These new generations can potentially replace diseased and damaged organs. By healing damaged cells, the result can be a reversal of and restoration of the aging process. As we age, cells become old and can no longer replace themselves with healthy cells. Cell therapy works at the cellular level to induce cells to reproduce. The goal is to repair or replace damaged cells with new cells.

The implications for a rapid and full recovery from everything from damaged brain cells to liver and kidney disease are enormous. We now have the potential to create healing where previously there was no hope of recovery.

Progenitor Xenotransplants and Cord Blood Cells are the stem cells of choice used by Progenacell Physicians. Most stem cell companies use one or the other, however Progenacell is the only company in the world that has perfected the use of both of these therapies combined as one treatment. Why the use of such?

  • These cells are young, potent cells able to regenerate damaged cells and build new cells.
  • Ease of undergoing changes in response to environmental or genetic factors.
  • Easy of adaptability (growth, migration, mobility, creation of cell-to-cell contacts).
  • More frequent and faster cell division and differentiation.
  • Production of large amounts of various growth factors.
  • Lowered immunogenicity.
  • Ability to survive on energy supplied by glycolysis and lower amounts of oxygen.
  • Lack of cell extensions easily damaged during processing of xenotransplantation.

Xeno Cells

Progenitor cells from animal origin are far more numerous than human stem cells with no special cell isolation procedures required for preparation. Progenitor cells live in a milieu of various earlier differentiated cells, with the primary benefit to the recipient being direct stimulation and regeneration of damaged cells rather than replacement of destroyed cells. Most patients receive cell transplantations of up to eleven different organ or tissue types, based upon the patho-physiology of the patient's disease(s). The more exact the patho-physiological, the more accurate the cell prescription.

No immune-suppression is required in clinical application of the cells. Of the estimated millions of patients treated worldwide, approximately 99% who underwent allogeneic or xenogeneic transplantation had absent immune-suppression. Xeno cells can be prepared from any vertebrate, e.g. man, fish, sheep, dog, etc. with the sole exception being the frontal lobe of the brain which animals lack. Thus any frontal lobe cell transplants should be of human fetal origin.

The scientific basis for the use of xenotransplantation relies on the principle of "organ-specificity." Key cells from the same organ or tissue are the same in all of nature, regardless of the species of origin, e.g. they are organ-specific (or tissue-specific) and not species-specific, and the same applies to any of over 200 kinds of cells found in human or animal bodies. Organ-specificity has been 'res ipsa loquitur' for European and USSR stem cell transplantologists for decades. Development of molecular cell biology during the last century was based on the fact that all eukaryotic cells are built and function according to the same laws. The great majority of proteins from different organisms (including man) are similar over the entire amino acid sequence, e.g. they are homologous with each other.

Cord Blood Cells

Cord blood cells come from human Umbilical Cords after a full-term natural birth. These cells generally number 100,000 to 300,000, but not enough for quantum healing. Skilled ProGenaCell scientists culture these cells in approved laboratories to amounts upwards from 10-50 million. These young, potent cells have the capability of traveling to injured, diseased and degenerative areas of the body and powerfully bringing about healthy changes. With these cells, there are virtually no instances of graft versus host disease or rejection issues. Cord blood-derived stem cells sport a good track record.

Cord blood was used therapeutically for the first time in 1988. Since then, a host of laboratory and human-use studies have been carried out that point to the fact that cord-blood therapy is of merit in treating various neurological diseases, autoimmune conditions, viral conditions and various blood diseases.

  • To Hear from a ProGenaCell Representative

    Fill out an Information Request Form Today! How can we help?